Beacon Pharmaceuticals Ltd.
Additional OffersShow all
Non-small Cell Lung Cancer, Indicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) ALK-positive, locall... View More
Should be taken with food: Swallow whole, do not open/dissolve the cap.
Non-small Cell Lung Cancer 600 mg PO BID until disease progression or unacceptable toxicity Dose reduction schedule Starting dose: 600 mg PO BID F... View More
Renal impairment Mild-to-moderate: No dose adjustment required Severe (CrCl <30 mL/min) or ESRD: Not studied
Mode of Action
Tyrosine kinase inhibitor that targets ALK and RET In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the... View More
Elevated liver enzymes reported; monitor liver function tests, including ALT, AST, and total bilirubin, q2weeks during the first 2 months of treatment, ... View More
>10% (All Grades) Anemia (56%) Increased AST (51%) Increased alkaline phosphatase (47%) Increased CPK (43%) Fatigue (26-41%) Hyperbilirubinemia (3... View More
Pregnancy Category Note
Pregnancy Based on animal studies and its mechanism of action, can cause fetal harm when administered to a pregnant woman There are no available data o... View More
May increase plasma conc of co-administered substrates of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) transporters (eg, digoxin, da... View More
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not... View More